HIGHLIGHTS
- who: Arun J. Sanyal from the (UNIVERSITY) have published the Article: Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial, in the Journal: (JOURNAL) of 11/03/2022
- what: The primary reason for treatment discontinuation was participant decision in the placebo and tropifexor 60-u03bcg groups and adverse events (AEs; n=4), participant/guardian decision (n=2) and physician decision (n=2) in the tropifexor 90-u03bcg group (Fig 1a). Insights into this analysis have been recently published31. In the current trial, the treatment period of 48 weeks may have been . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.